Characterization of acute renal allograft rejection by human serum proteomic analysis

Ying Gao, Ke Wu, Yi Xu, Hongmin Zhou, Wentao He, Weina Zhang, Lanjun Cai, Xingguang Lin, Zemin Fang, Zhenlong Luo, Hui Guo, Zhonghua Chen

Current Medical Science ›› 2009, Vol. 29 ›› Issue (5) : 585-591.

Current Medical Science ›› 2009, Vol. 29 ›› Issue (5) : 585-591. DOI: 10.1007/s11596-009-0511-8
Article

Characterization of acute renal allograft rejection by human serum proteomic analysis

Author information +
History +

Abstract

To identify acute renal allograft rejection biomarkers in human serum, two-dimensional differential in-gel electrophoresis (2-D DIGE) and reversed phase high-performance liquid chromatography (RP-HPLC) followed by electrospray ionization mass spectrometry (ESI-MS) were used. Serum samples from renal allograft patients and normal volunteers were divided into three groups: acute rejection (AR), stable renal function (SRF) and normal volunteer (N). Serum samples were firstly processed using Multiple Affinity Removal Column to selectively remove the highest abundance proteins. Differentially expressed proteins were analyzed using 2-D DIGE. These differential protein spots were excised, digested by trypsin, and identified by RP-HPLC-ESI/MS. Twenty-two differentially expressed proteins were identified in serum from AR group. These proteins included complement C9 precursor, apolipoprotein A-IV precursor, vitamin D-binding protein precursor, beta-2-glycoprotein 1 precursor, etc. Vitamin D-binding protein, one of these proteins, was confirmed by ELISA in the independent set of serum samples. In conclusion, the differentially expressed proteins as serum biomarker candidates may provide the basis of acute rejection noninvasive diagnosis. Confirmed vitamin D-binding protein may be one of serum biomarkers of acute rejection. Furthermore, it may provide great insights into understanding the mechanisms and potential treatment strategy of acute rejection.

Keywords

acute rejection / two-dimensional differential in-gel electrophoresis / reversed phase high-performance liquid chromatography / electrospray ionization mass spectrometry / ELISA / serum

Cite this article

Download citation ▾
Ying Gao, Ke Wu, Yi Xu, Hongmin Zhou, Wentao He, Weina Zhang, Lanjun Cai, Xingguang Lin, Zemin Fang, Zhenlong Luo, Hui Guo, Zhonghua Chen. Characterization of acute renal allograft rejection by human serum proteomic analysis. Current Medical Science, 2009, 29(5): 585‒591 https://doi.org/10.1007/s11596-009-0511-8

References

[1]
HariharanS., JohnsonC.P., BresnahanB.A., et al.. Improved graft survival after renal transplantation in the United States, 1998–1996. N Engl J Med, 2000, 342(9): 605-612
CrossRef Google scholar
[2]
McLarenA.J., FuggleS.V., WelshK.I., et al.. Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis. Ann Surg, 2000, 232(1): 98-103
CrossRef Google scholar
[3]
BenfieldM.R., HerrinJ., FeldL., et al.. Safety of kidney biopsy in pediatric transplantation: a report of the controlled clinical trials in pediatric transplantation trial of induction therapy study group. Transplantation, 1999, 67(4): 544-547
CrossRef Google scholar
[4]
TraumA.Z., SchachterA.D.. Transplantation proteomics. Pediatr Transplant, 2005, 9(6): 700-711
CrossRef Google scholar
[5]
SolezK., ColvinR.B., RacusenL.C., et al.. Banff’ 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (’CAN’). Am J Transplant, 2007, 7(3): 518-526
CrossRef Google scholar
[6]
PengJ., EliasJ.E., ThoreenC.C., et al.. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res, 2003, 2(1): 43-50
CrossRef Google scholar
[7]
AndersonN.L., PolanskiM., PieperR., et al.. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics, 2004, 3(4): 311-326
CrossRef Google scholar
[8]
HuangH.L., StasykT., MorandellS., et al.. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis, 2006, 27(8): 1641-1650
CrossRef Google scholar
[9]
SchaubS., WilkinsJ.A., NickersonP.. Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets. Contrib Nephrol, 2008, 160: 65-75
CrossRef Google scholar
[10]
ClarkeW.. Proteomic research in renal transplantation. Ther Drug Monit, 2006, 28(1): 19-22
CrossRef Google scholar
[11]
SchaubS., WilkinsJ.A., AntonoviciM., et al.. Proteomic-based identification of cleaved urinarybeta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant, 2005, 5(4Pt1): 729-738
CrossRef Google scholar
[12]
WittkeS., HaubitzM., WaldenM., et al.. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant, 2005, 5(10): 2479-2488
CrossRef Google scholar
[13]
El EssawyB., OtuH.H., ChoyB., et al.. Proteomic analysis of the allograft response. Transplantation, 2006, 82(2): 267-274
CrossRef Google scholar
[14]
VosholH., BrendlenN., MüllerD., et al.. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res, 2005, 4(4): 1192-1199
CrossRef Google scholar
[15]
YuK.H., RustgiA.K., BlairI.A.. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res, 2005, 4(5): 1742-1751
CrossRef Google scholar
[16]
SchiødtF.V., RossaroL., StravitzR.T., et al.. Gc-globulin and prognosis in acute liver failure. Liver Transpl, 2005, 11(10): 1223-1227
CrossRef Google scholar
[17]
SpeeckaertM.M., GlorieuxG.L., VanholderR., et al.. Vitamin D binding protein and the need for vitamin D in hemodialysis patients. J Ren Nutr, 2008, 18(5): 400-407
CrossRef Google scholar
[18]
ZellaL.A., ShevdeN.K., HollisB.W., et al.. Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology, 2008, 149(7): 3656-3667
CrossRef Google scholar
[19]
ChristakosS., DhawanP., LiuY., et al.. New insights into the mechanisms of vitamin D action. J Cell Biochem, 2003, 88(4): 695-705
CrossRef Google scholar
[20]
MathieuC., JafariM.. Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol, 2006, 66(4): 275-283
[21]
KogaY., NaraparajuV.R., YamamotoN.. Antitumor effect of vitamin D-binding protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing mice. Proc Soc Exp Biol Med, 1999, 220(1): 20-26
CrossRef Google scholar
[22]
YamamotoN., SuyamaH., UshijimaN.. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer, 2008, 122(2): 461-467
CrossRef Google scholar
[23]
YamamotoN., SuyamaH.. Immunotherapy for prostate cancer with gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol, 2008, 1(2): 65-72
[24]
NickeleitV., AndreoniK.. Inflammatory cells in renal allografts. Front Biosci, 2008, 13: 6202-6213
CrossRef Google scholar
[25]
QiF., AdairA., FerenbachD., et al.. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation, 2008, 86(9): 1267-1274
CrossRef Google scholar

This project was supported by a grant from National Basic Research 973 Program of China (No. 2009CB522407).

Accesses

Citations

Detail

Sections
Recommended

/